We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · July 29, 2021

Standard Prophylactic- vs Intermediate-Dose Enoxaparin in Adults With Severe COVID-19

Journal of Thrombosis and Haemostasis (JTH)


Additional Info

Journal of Thrombosis and Haemostasis (JTH)
Standard Prophylactic Versus Intermediate Dose Enoxaparin in Adults With Severe COVID-19: A Multi-Center, Open-Label, Randomized Controlled Trial
J. Thromb. Haemost. 2021 Jul 08;[EPub Ahead of Print], US Perepu, I Chambers, A Wahab, P Ten Eyck, C Wu, S Dayal, G Sutamtewagul, SR Bailey, LJ Rosenstein, SR Lentz

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading